Boston Scientific (NYSE:BSX) Stock Moved Down to “Hold” by TD Cowen

TD Cowen downgraded shares of Boston Scientific (NYSE:BSX) from a buy rating to a hold rating in a research report released on Friday, MarketBeat Ratings reports. The firm currently has $46.00 target price on the medical equipment provider’s stock, down from their prior target price of $56.00.

BSX has been the subject of several other reports. Truist Financial decreased their price target on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Robert W. Baird raised their target price on shares of Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday. Mizuho set a $50.00 target price on Boston Scientific in a research note on Thursday. Finally, Sanford C. Bernstein lowered their target price on Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Price Performance

BSX opened at $41.93 on Friday. The company has a market capitalization of $60.77 billion, a P/E ratio of 13.38, a PEG ratio of 1.05 and a beta of 0.58. The company has a 50-day moving average of $44.78 and a 200-day moving average of $56.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific has a 1-year low of $39.57 and a 1-year high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 earnings per share. Equities analysts expect that Boston Scientific will post 3.17 EPS for the current fiscal year.

Insider Activity

In other news, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael Mahoney bought 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 189,522 shares of company stock worth $9,157,810. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific during the first quarter valued at about $28,000. Cassaday & Co Wealth Management LLC acquired a new position in Boston Scientific during the first quarter worth about $32,000. Measured Wealth Private Client Group LLC raised its position in Boston Scientific by 244.9% in the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 387 shares in the last quarter. Kelleher Financial Advisors bought a new stake in Boston Scientific in the second quarter worth about $25,000. Finally, Nvwm LLC lifted its holdings in Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 542 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.